Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation?

Transplant Proc. 2006 Jun;38(5):1329-32. doi: 10.1016/j.transproceed.2006.02.069.

Abstract

The aim of our study was to assess the long-term liver histology in renal transplant patients infected with hepatitis C virus (HCV) who were treated with a cyclosporine-based regimen. Among 55 anti-HCV+/RNA+ patients, liver biopsies (LB) were requested every 3 to 4 years after transplantation: two LBs (n=55); three LBs (n=44); four LBs (n=10). Overall, the rate of liver fibrosis progression was 0.07+/-0.03 Metavir U/y. Only three patients out of 55 (5.4%) developed cirrhosis. Liver fibrosis remained stable throughout follow-up in 21 patients; increased in 21 patients; and improved in the remaining 13 patients. The incidence of posttransplant diabetes mellitus was low (9%). We concluded that HCV infection is not harmful to liver histology in more than 50% of renal transplant patients with grafts functioning more than 6 years. Cyclosporine might have beneficial effects on the natural course of HCV infection after renal transplantation.

MeSH terms

  • Adult
  • Cyclosporine / therapeutic use*
  • Female
  • Follow-Up Studies
  • Genotype
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Kidney Transplantation / immunology*
  • Male
  • RNA, Viral / genetics
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Viral Load

Substances

  • RNA, Viral
  • Cyclosporine